Pharma modernization initiatives stall not from lack of ambition but from expanding governance layers that distance ...

In this video interview, Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fisher ...

In today's ACT Brief, we explore why clinical trial diversity requires protocol redesign from the outset, the highest-impact ...

In today's ACT Brief, we explore why clinical trial diversity requires protocol redesign from the outset, the highest-impact opportunities for AI across the complete trial lifecycle, and the ...

In part 3 of this three-part series, behavioral science reveals that clinical trial diversity cannot be achieved through last ...

At the 2026 SCOPE Summit in Orlando, Florida, ACT caught up with Miriam Dervan, founder and CEO of mdgroup. In an exclusive interview, Dervan discussed how prioritizing the patient experience early in ...

C.K Wang, MD General Manager of Oncology & Chief Medical Officer Verana Health C.K. Wang is the General Manager of Oncology ...

In a recent video interview with Applied Clinical Trials, Krishna Cheriath, vice president and head of clinical research ...

In today's ACT Brief, we examine the technical and operational challenges of implementing risk-based monitoring across global ...

Global RBM requires interoperable architectures across EDC, IRT, eCOA, labs, imaging, EHR, and safety systems, but inconsistent CDISC/HL7 FHIR adoption and proprietary APIs impede near–real-time ...

Risk-based monitoring requires integrated data systems, validated analytics, and strong governance to work effectively across global trials, but sponsors face significant technical and operational ...

In a recent video interview with Applied Clinical Trials, Krishna Cheriath, vice president and head of clinical research digital data and AI at Thermo Fish ...